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Abstract
Background: 177Lu-DOTATATE is a valuable treatment option for patients with
advanced neuroendocrine tumours overexpressing somatostatin receptors. Though well
tolerated in general, bone marrow toxicity can, besides renal exposure, become dose
limiting and affect the ability to sustain future therapies. The aim of this study
was to develop a novel planar image-based method for bone marrow dosimetry
and evaluate its correlation with haematological toxicity during 177Lu-DOTATATE
treatment. In this study, 46 patients with advanced neuroendocrine tumours
were treated with 7.2 GBq (3.5–8.3 GBq) of 177Lu-DOTATATE on two to five
occasions. Planar gamma camera images were acquired at 2, 24, 48 and 168 h
post-injection. Whole-body regions of interest were created in the images, and
a threshold-based segmentation algorithm was applied to separate the uptake
of 177Lu-DOTATATE into high and low uptake compartments. The conjugate
view method was used to quantify the activity, the accumulated activity was
calculated and the absorbed dose to the bone marrow was estimated according
to the MIRD scheme. Patients were monitored for haematological toxicity based
on haemoglobin (Hb), white blood cell (WBC) and platelet (PLT) counts every
other week during the treatment period.
Results: The mean absorbed dose to the bone marrow was estimated to 0.20 Gy
(0.11–0.37 Gy) per 7.4 GBq of 177Lu-DOTATATE, and the mean dose per fraction
correlated with a decrease in Hb (p = 0.01), WBC (p < 0.01) and PLT (p < 0.01) counts.
The total mean absorbed dose to the bone marrow was 0.64 Gy (0.30–1.5 Gy) per
24 GBq (8.2–37 GBq) of 177Lu-DOTATATE and also correlated with a decrease in Hb
(p < 0.01), WBC (p = 0.01) and PLT (p < 0.01) counts.
Conclusions: The planar image-based method developed in this study resulted in
similar absorbed doses to the bone marrow as reported in earlier studies with blood-
based bone marrow dosimetry. The results correlated with haematological toxicity,
making it a promising method for estimating bone marrow doses in 177Lu-DOTATATE
treatment without the need for blood and urine sampling.
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Background
Treatment with 177Lu-labelled somatostatin analogues (177Lu-DOTATATE) for patients
with advanced neuroendocrine tumours has been proven safe and efficient [1–3]. The
bone marrow is considered the most important dose-limiting organ besides the kidneys
[1, 2, 4]. Clinical protocols for 177Lu-DOTATATE treatment routinely include mean
absorbed dose estimates for the kidneys [1, 2, 5], which usually decide the number of
fractions given because of a defined dose limit, even though clinically relevant renal
toxicity seldom is observed [6, 7]. In contrast, bone marrow dosimetry is only per-
formed occasionally, and instead haematological toxicity monitored in terms of haemo-
globin (Hb), white blood cell (WBC) and platelet (PLT) counts serves as a surrogate of
bone marrow function. Haematological toxicity is often present during 177Lu-DOTA-
TATE treatment and is accepted, as it usually is mild and transient [1, 2, 8]. However,
serious haematological toxicity (grade 3–4 according to NCI CTCAE version 3.0) is
reported in 10 % of treated patients, and long-term effects in terms of myelodysplastic
syndrome or leukaemia are described in 1–2 % of treated patients [1, 9].
The most accepted mean absorbed dose limit to the bone marrow for PRRT is 2 Gy
[1, 10], which was originally set based on experiences with 131I therapy for the treat-
ment of thyroid cancer [11–13]. The methods used to estimate the absorbed dose to
the bone marrow in radionuclide therapy is based on the MIRD scheme [14], which
includes the absorbed dose from charged particles and photons in the bone marrow
itself (self-dose) and the absorbed dose due to the photon radiation from activity
distributed in the remainder of the body (cross-dose). Most often described is an indir-
ect method to estimate the absorbed dose that includes repeated blood sampling after
therapy to obtain activity concentration estimates, the acquisition of post-therapeutic
gamma camera images and sometimes urine sampling (Table 1) [2, 15–18]. This indir-
ect method for bone marrow dosimetry was first described and utilised for radioimmu-
notherapy [19] and later for PRRT [16, 17].
Blood-based dosimetry relies on the assumption of a specific ratio between the activ-
ity concentrations in blood and bone marrow. This ratio has been considered to be
close to 1 for radionuclide therapy using peptides, assuming low or no specific binding
of the radionuclide in the bone marrow [20], which was confirmed in a study with
177Lu-DOTATATE in which bone marrow and blood samples collected at the same
time points were analysed [16].
Changes in Hb, WBC and PLT counts after treatment do not necessarily describe the
magnitude of the radiation exposure, as the estimated dose to the bone marrow not
Table 1 Studies on blood and image-based bone marrow dosimetry in 177Lu-DOTATATE
treatment
Author, year Number of patients Method BM dose (Gy/7.4 GBq)
Wehrmann, 2007 27 Blood, imaging 0.30
Forrer, 2009 13 Blood, urine, imaging 0.25
Bodei, 2011 12 Blood, imaging 0.25
Sandström, 2013 200 Blood, urine, imaging 0.12 median
Jackson, 2013 28 Imaging 0.11–0.26
Bergsma, 2016 23 Blood, urine, imaging 0.50
Present study, 2016 46 Imaging 0.20
No number BM bone marrow
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has been proven to correlate with haematological toxicity [9, 16]. Reasons for this are
both uncertainties in the methods used to estimate the dose, and that several other fac-
tors affect the haematological response, including baseline WBC counts, patient age,
renal function, previous chemotherapy, large tumour burden, bone metastases and
splenectomy [8, 9, 18, 21]. Regardless of the dose-response relationship, an estimation
of the mean absorbed dose to the bone marrow in PRRT must be considered important
because its viability will set the limits for future therapies affecting the bone marrow
and affect the risk of developing serious long-term toxicity.
The aim of our study was to develop a novel method for bone marrow dosimetry
based on planar post-therapy imaging, without the need for blood and urine sampling,
and to investigate a possible correlation with haematological toxicity.
Methods
Patients and treatment characteristics
A total of 46 patients at Sahlgrenska University Hospital, who were diagnosed with ad-
vanced neuroendocrine tumours, were included in this retrospective study. The study
was approved by the Regional Ethics Review Board in Gothenburg and performed in
accordance with the principles of the Declaration of Helsinki and national regulations.
The need for written informed consent was waived. Patients considered for treatment
had a progressive disease; clinically or radiologically. They were judged to have tumours
over-expressing somatostatin receptors (i.e. uptake exceeding physiological liver uptake)
based on somatostatin receptor scintigraphy (Octreoscan®). 177Lu-DOTATATE was
administered at an activity of 7.2 ± 1.3 GBq (3.5–8.3 GBq) on two to five occasions,
approximately 8 weeks apart, to a total mean activity amount of 24 ± 7.2 GBq (8.2–
37 GBq). Each fraction was given as a 30-min intravenous infusion coadministered with
kidney-protective amino acids (2.5 % lysine and 2.5 % arginine in 1 L of 0.9 % NaCl; in-
fusion rate 250 mL/h). The number of fractions was decided from received renal dose
(limit 27 Gy) or persisting haematological toxicity or disease progression.
Image acquisition
For this planar dosimetry method based on the conjugate view method, anterior and
posterior planar images were acquired at 2, 24, 48 and 168 h post-injection (p.i.). A
SPECT/CT was acquired 24 h p.i. for calibration purposes. The gamma cameras were a
Picker IRIX (Marconi, Phillips, Holland) and a Millennium VG Hawkeye (General
Electric Medical Systems, Milwaukee, WI, USA) equipped with medium energy
parallel-hole collimators. Planar whole-body scans were performed with a scanning
time of 10 min and a 20 % energy window over the 208-keV photon peak. Measure-
ment over the 113-keV photon peak was omitted due to the high scattering fraction in
the data. No further scatter correction was included in the protocol. The SPECT image
acquisition used the same energy setting and was performed with 30-s frame duration
for 120 projections. The CT images were acquired using 140-kV tube voltage, 2.5 mAs,
and a rotation speed of 2.6 rpm. SPECT reconstructions were performed using the
ordered subset expectation maximum (OSEM) algorithm with two iterations, 10
subsets and post-filtering. No scattering window was used. The effective attenuation
coefficient and the sensitivity for the gamma cameras were determined by scintigraphy
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of a planar 177Lu source placed at different depths in a phantom of tissue equivalent
material. A region of interest was drawn around the source in the planar images and
the counts recorded after which a monoexponential curve was fitted to the number of
counts versus depth data.
The planar two-compartment method
The method for planar image dosimetry was based on a two-compartment approach
that separated the high uptake area from the low uptake area in geometric mean
images produced from the anterior and posterior whole-body images. To avoid oper-
ator dependence, an automated algorithm was created for the compartment separation.
In this automated algorithm, a Butterwort low pass filter at order 2 with a cut-off
frequency of 0.03 filtered the geometric mean images, and a contour line algorithm was
used to obtain the whole-body region of interest (ROI). Filtering the images was espe-
cially important for the 7 day p.i. images, as the noise level would otherwise hamper
the accuracy of the whole-body outline. The whole-body ROI was then transposed onto
the unfiltered geometric mean images. In the whole-body ROI, the pixels with a value
(counts) higher or equal to a specific value (threshold) were identified with a threshold
algorithm. This was done for all pixel values, from the maximum value and down to 0.
At each threshold value, the number of connected pixel regions (i.e. uptake foci) was
determined in the whole-body by a connected-component labelling algorithm [22]. The
number of uptake foci (NUF) was calculated at each threshold value, generating a
distribution of NUF versus a threshold index (ThI) defined as
ThI ¼ Cmax− Cthr
Cmax
ð1Þ
where Cmax is the maximum pixel value in the whole-body ROI and Cthr is the pixel
threshold value. The NUF was normalized (nNUF) to the maximum number of uptake
foci and could then be described as a function of ThI, ranging from 0 to 1. The
algorithm was implemented into the medical physics, oncology and nuclear medicine
image research platform at the Sahlgrenska Academy (PhONSAi) [22].
The distribution of nNUF versus ThI was analysed for all images to define an appro-
priate nNUF threshold value separating the whole-body into high and low uptake
compartments. The high uptake compartment includes organs with physiologically or
pathologically high somatostatin receptor expression, such as the liver, spleen, kidneys
and tumours. The low uptake compartment corresponds to the remainder of the body.
The defined nNUF threshold value was applied to all time points and all patients.
Dosimetry
The activity in the two compartments was quantified according to the conjugate view
method and time-activity curves created [23]. For the conjugate view calculations, the
patient-specific thickness of the high uptake compartment was determined over the
abdomen by a high-resolution CT and the activity assumed to be concentrated to a
volume with a general organ thickness determined from a series of measurements in
SPECT images (8 cm). The weight of the high uptake compartment was determined by
assuming a density of unity and calculating the volume from the abdominal thickness
and the area of the high uptake compartment. In the low uptake compartment, the
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activity was assumed to be uniformly distributed, and the thickness was determined as
the patient-specific weight minus the calculated weight of the high uptake compart-
ment divided by the area of the low uptake compartment. The accumulated activity in
the under- and overlying tissue of the high uptake compartment was added to the low
uptake compartment.
When four data points were available, the data for the low uptake compartment was
fitted to a bi-exponential function, and when 3 data points were available to a mono-
exponential function. For the high uptake compartment, data from the 2 and 24 h p.i.
images were fitted to a linear function and data from 24 h p.i. and later time points
were fitted to a mono-exponential function. The curves were extrapolated to the time
of injection (t = 0). The accumulated activity was determined by calculating the area
under the curve.
SPECT/CT measurements were performed to verify the relationship between the
activity concentration in the bone marrow and the low uptake compartment, which
was considered to consist mainly of muscle, fat and bone. This was achieved by apply-
ing one volume of interest (VOI) in the centre of a lumbar vertebra (L4) to represent
the bone marrow and another VOI symmetrically located around L4 to represent the
low uptake compartment.
The partial volume effect was determined, and corrected for, by an experimentally
determined recovery correction (RC) factor. For this, the bone marrow VOI described
above, was placed in the CT image. Activity was then placed in the VOI, and the
photon emission and the photon absorption within and outside the VOI was simulated
by the Monte Carlo program implemented in the image platform PhONSAi [22].
The ratio between the recovery corrected activity concentration in the bone marrow
VOI and the activity concentration in the VOI representing the low uptake compart-
ment was determined from 53 SPECT/CT images of 15 patients without known
tumour infiltration in the bone marrow or the tissue surrounding the VOI. To have
similar inscattering conditions, the tissue directly surrounding the bone marrow VOI
was chosen, representing the low uptake compartment. The tissue of these VOIs was
dominated by muscle, fat and connective tissue, with some bone also included, which
may be considered representative of the low uptake compartment of the whole body.
The ratio of the activity concentrations in the bone marrow and the low uptake
compartment was assumed to be constant over time. L4 was chosen because it could
be defined on CT to its size and horizontal orientation.
The mean absorbed dose to the bone marrow (Dbm) was calculated as the sum of the
self-dose from the charged particles in the bone marrow itself and the cross-doses (γ
radiation) from the high and low uptake compartments as follows:
Dbm ¼ Aebm  Sbm←bm þ Aehigh  Sbm←high þ Aelow  Sbm←low ð2Þ
where the accumulated activity in the bone marrow (Ãbm) was derived from the accu-
mulated activity in the low uptake compartment (Ãlow) and adjusted by the calculated
ratio of the activity concentrations in the bone marrow and the low uptake compart-
ment. The S values were obtained from the specific absorbed fractions defined on the
RADAR website [24]. The S value for the gamma contribution from the high uptake
compartment was calculated as a weight-weighted mean of the S values for the liver,
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spleen and kidneys (Sbm←high), and from the low uptake area as a mean of the S values
for muscle and bone (Sbm←low).
Monitoring bone marrow function
Bone marrow function was monitored during treatment in terms of Hb, WBC and PLT
counts in blood every other week. To evaluate whether the mean absorbed dose to the
bone marrow affected the development of haematological toxicity, the mean absorbed
dose per fraction and the total absorbed dose to the bone marrow were compared to
the nadir values for Hb, WBC and PLT counts during treatment.
Statistical analysis
The association of a decrease in blood counts from baseline values in the study popula-
tion and the absorbed dose to the bone marrow was examined by analysis of variance
(ANOVA) in linear regression analysis. All imaging data were fitted using MATLAB®
and the coefficient of determination (R2) calculated. p values <0.05 were considered
significant.
Results
The methodology for the planar image dosimetry was straightforward and robust.
Visual analysis of nNUF versus ThI dependence revealed a similar pattern in all images
(Fig. 1). The number of foci gradually increased as the ThI increased, until a threshold
was reached and the number of foci increased substantially. This threshold value, used
as the cut-off between the high and low uptake compartments, was 0.1, implying that
10 % of the foci are included in the high uptake compartment and the remaining 90 %
in the low uptake compartment. The sensitivity of the threshold value was tested for by
changing its value between 0.05 and 0.25 and the mean absorbed bone marrow doses
varied up to 10 % in this interval. No significant difference was observed in the coeffi-
cient of variation (8.5–8.9 %) for the individual mean absorbed doses when varying the
threshold value between 0.05 and 0.25.
Time-activity curves for the low uptake compartment were fitted to a bi-exponential
function when four time points were available (165/174 fractions; Fig. 2). For patients
with only three data points, the time-activity curve was fitted to a mono-exponential
function. The effective half-lives for the first and second phases in the low uptake com-
partment were 2.4 ± 1.7 h (1.0–11 h) and 61 ± 9.2 h (43–89 h), respectively. For the
high uptake compartment, the time-activity curves for all patients were fitted to a linear
function for the first phase and a mono-exponential function for the second phase, with
an effective half-life for the second phase of 69 ± 14 h (12–102 h) (Fig. 2). In 28 % of
these time-activity curves, there was an initial uptake phase (0–24 h). Most of the accu-
mulated activity in the whole body, 63 ± 11 % (23–90 %), was deposited in the high
uptake compartment and 37 ± 11 % (10–77 %) in the low uptake compartment.
Figure 3 illustrates a delineated bone marrow VOI (Vmean = 8 mm
3) in the lumbar
spine and a surrounding VOI (Vmean = 34 mm
3) representing the low uptake compart-
ment in a horizontal CT slice. The recovery corrected ratio between the bone marrow
and low uptake compartment activity concentrations was estimated to 1.8 (1.4–2.8).
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Fig. 1 Illustration of the segmentation technique used to divide the activity uptake into a high and a low
uptake compartment. A region of interest of the whole body (a). The automated segmentation tool
includes foci in the whole body starting with the highest uptake foci to the left on the x-axis (b). Moving
to the right, more and more foci will be included (normalized number of uptake foci on the y-axis) until a
threshold is reached (c), just before the number of foci increases and the noise is included (d). The cut-off
between the high and low uptake compartments (nNUF = 0.1) is set at the threshold value illustrated
in (c) nNUF normalized number of uptake foci ThI threshold index
Fig. 2 An example of the clearance of the low uptake compartment illustrated as a time-activity concentration
curve (t½ 1stphase 2.4 h, t½ 2ndphase 61 h for all patients) (a), and the clearance of the high uptake compartment
illustrated as a time-activity curve (t½ 2ndphase 69 h for all patients) (b)
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The mean absorbed dose to the bone marrow for the 46 patients included in this
study was estimated to 0.20 ± 0.05 Gy (0.11–0.37 Gy) per 7.4 GBq of 177Lu-DOTA-
TATE. The variation in mean absorbed dose between treatments is illustrated in Fig. 4.
The coefficient of variation (CV) for the individual mean absorbed bone marrow doses
was 0.08. For all fractions, the mean total absorbed dose was 0.64 ± 0.22 Gy (0.30–
1.5 Gy) from a total amount of 24 ± 7.2 GBq (8.2–37 GBq) 177Lu-DOTATATE. The
self-dose dominated, contributing 85 ± 4.0 % (61–92 %) of the total absorbed dose to
the bone marrow. The cross-doses from the high and low uptake compartments con-
tributed 8.9 ± 3.6 % (2–23 %) and 5.8 ± 1.9 % (1.4–25 %) of the total dose, respectively.
Correlations were found between the calculated mean absorbed dose to the bone
marrow per treatment and the decrease in Hb (Pearson r = −0.36, p = 0.01), WBC
(r = −0.43, p < 0.01) and PLT counts (r = −0.45, p < 0.01). In addition, a higher total absorbed
dose to the bone marrow was associated with the decrease in Hb (r = −0.45, p < 0.01), WBC
(r = −0.36, p = 0.01) and PLT counts (r = −0.43, p < 0.01; Fig. 5).
Discussion
This novel planar image-based method for bone marrow dosimetry yields estimated
mean absorbed doses of 0.20 Gy per 7.4 GBq of 177Lu-DOTATATE, which is compar-
able to other published series on blood-based bone marrow dosimetry for this
Fig. 3 Cross-section of an abdominal CT scan with a delineated volume of interest (VOI) around the bone
marrow in the lumbar spine (L4) and a surrounding VOI representing the low uptake compartment in the
whole body (a) and a posterior view of a SPECT image illustrating the localisation of lumbar spines L1–L5

































Fig. 4 The variation in absorbed dose to the bone marrow between treatments for the 46 individual
patients (cv = 0.08). The gray-dotted line represents the mean absorbed dose per treatment for all patients,
0.20 Gy. No number
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treatment (Table 1). The correlation with haematological toxicity is significant but not
patient-specific due to large variations in the established correlation. There are several
possible reasons for the lack of a more apparent dose-response relationship with this
method and also with blood-based dosimetry. Blood-based methods have uncertainties,
including the timing and handling of the blood samples and calibration of the instru-
ments. The method developed in this study to divide the whole-body uptake into two
compartments in an automated manner seems feasible but will share the uncertainties
included in all planar dosimetry approaches. Furthermore, both this image-based
method and blood-based dosimetry involve an indirect estimation of the activity
concentration in the bone marrow and choosing a ratio for the compartment that is
quantified to the bone marrow. The ratio in this study was based on a mean value for
the ratio between the measured activity concentration in a lumbar vertebra (L4), repre-
senting the bone marrow, and a VOI drawn around the same vertebra, representing the
low uptake compartment in the 24-h SPECT in patients without bone metastases. The
ratio is then applied to all patients, possibly underestimating the ratio for patients with
extensive bone involvement. Any inscattering is assumed to be equal to the two VOIs;
however, this will lower the ratio between the two VOIs, which may further underesti-
mate the obtained ratio. Another aspect is the possible difference in the kinetics of the
radiopharmaceutical in the low uptake compartment compared to the bone marrow,
which may lead to an overestimation or underestimation of the absorbed dose to the
















































































































































Fig. 5 Mean absorbed doses and total absorbed doses to the bone marrow correlated with the decrease in
Hb (a, b), WBC (c, d) and platelet (e, f) counts respectively during 177Lu-DOTATATE treatment
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A direct measurement of the activity concentration in the bone marrow is described
for 177Lu-DOTATATATE, and a ratio of 1 was found to the activity concentration in
blood at the same time point [16]. Following the activity concentration and its kinetics
directly by frequent bone marrow sampling could be considered the most accurate
method but is not practicable. Even with only one bone marrow sample, this method
would not describe the possible regional differences in bone marrow distribution or
activity concentration [25].
The self-dose dominated the contributions to the absorbed dose to the bone marrow,
just as Sandström et al. observed, though to a lesser extent (85 versus 65 %) [17], using
blood-based dosimetry. In contrast, Forrer et al. calculated that approximately one third
of the absorbed dose to the bone marrow was derived from the self-dose in blood-
based dosimetry [16]. In that study, the contribution from the remainder of the body
was intentionally overestimated from the activity quantification in urine sampled for
the first 24 h p.i.
Another aspect to consider when comparing dose estimates between studies is that
different S values may be used, from either the original MIRD Pamphlet No. 11 or
newer phantoms, including data published on the RADAR website, where S values have
been reduced in general [24]. The weighted S values produced in this study to calculate
the cross-doses from the high and low uptake compartments are simplified but should
be useful in most cases, as their contribution was generally low.
Further optimization of the presented method would be valuable to explore whether
improved correlations can be found for the absorbed dose to the bone marrow and
haematological toxicity. Strategies should include the use of simulated planar images
from different sized phantom measurements to explore the optimal threshold NUF and
selecting more patient-specific S values for cross-doses. The use of different scattering
correction techniques and methodologies for attenuation correction, such as scout
images, is another factor to explore.
Pure image-based methods to estimate the absorbed dose to the bone marrow in
radionuclide therapy have been described previously, and originally for radioimmu-
notherapy, by Siegel et al. [26] based on quantification of the accumulated activity
in the sacral region in the post-therapeutic planar images. Forrer et al. [16] also
evaluated an image-based method to estimate the accumulated activity of 177Lu-
DOTATATE in the bone marrow by quantifying the activity concentration in the
thoracic spine from SPECT images after therapy. However, the authors concluded
that the spine uptake was too close to background values. In a recent study, an
image-based method for bone marrow dosimetry in 177Lu-DOTATATE treatment
was presented using repeated SPECT images for voxel-based quantification of the
radioactivity in the lumbar spine [27], but the method was not verified against
haematological toxicity. Despite the uncertainties in the presented method, it
showed a dose-response relationship between absorbed bone marrow dose and
haematological toxicity according to Hb, WBC and PLT counts for both mean and
total absorbed dose. One previous study, recently performed by Bergsma et al., ob-
served a correlation between cumulative bone marrow dose and WBC and PLT
counts, not Hb, in a sub-group analysis of 14 patients [18].
The estimation of the bone marrow exposure needs to be as accurate as possible, but
the haematological response will only be fully understood when also other clinical data
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for the patient is considered, as renal function, tumour burden, baseline blood values
and age [18, 21] as well as the individual radiosensitivity.
The correlation with haematological toxicity encourage further development of the
method described for bone marrow dosimetry to increase the accuracy of absorbed
dose estimates and the correlation to haematological response. A sub-study including
blood-based dosimetry to compare the method for the individual patient is initiated in
the ongoing prospective phase II study on 177Lu-DOTATATE treatment for patients
with progressive neuroendocrine tumours (ILUMINET, EudraCT 2011-000240-16)
Conclusions
This study presents a novel image-based method for bone marrow dosimetry depending
mainly on planar imaging with correlation to haematologic toxicity. The results
encourage to further development of the method, aiming to increase the accuracy in the
absorbed dose estimates and its correlation to haematological response. The need for
individual BM dosimetry grows as the total amount of 177Lu-DOTATATE given tends to in-
crease and future treatment options make it necessary to preserve bone marrow function.
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